# How Long Do Semaglutide and Tirzepatide Side Effects Last?

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-14 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last

> What predicts side effects is where you are on the ladder, not how many weeks you have been taking it. Both labels place the nausea and diarrhea during escalation, and how long any single dose keeps working comes down to half-life: roughly seven days for semaglutide, roughly five for tirzepatide.

## Key points

- Both approved labels place the nausea, vomiting and diarrhea during dose escalation rather than spread across treatment, so the useful coordinate is the ladder, not the week number.
- Semaglutide's half-life is about one week and the drug is still in circulation roughly five weeks after a last dose, or up to seven at the higher Wegovy doses; tirzepatide's is about five days.
- Wegovy's label documents dysesthesia at 7.2 mg in 22% of patients, and 18% of those who had it reported no recovery by the trial's end, so not everything settles.
- Severe abdominal pain reaching through to the back, vomiting past a day with no fluids staying down, jaundice with upper-abdominal pain, or throat swelling go to a clinician the same day.
- A large cohort study found similar rates of severe gastrointestinal events across dulaglutide, semaglutide and tirzepatide, so switching molecules is not a guaranteed fix.

Where you are on the dose ladder predicts how you feel far better than how many weeks you have been treated. Both approved labels and both pivotal obesity trials put the nausea, vomiting and diarrhea in the escalation phase, not spread evenly across a year.[1][3][5][6] The other half of the answer is pharmacokinetic and rarely mentioned. Semaglutide's half-life runs to roughly seven days and tirzepatide's to roughly five, so a weekly injection never fully wears off between doses, and its effects do not stop on a set day.[1][4]

> **Some symptoms are not a waiting question.** Abdominal pain that is severe or will not settle, especially if it goes through to your back; vomiting past a day with nothing staying down; swelling around the mouth, the tongue or the throat, or trouble breathing. Those go to a clinician the same day, and the last one goes to emergency care. Everything below is background, not triage.

## The clock that matters is the escalation clock

Both labels say the same thing in almost the same words, and it is the single most useful sentence in either document. Zepbound's prescribing information records that most of the nausea, the vomiting and the diarrhea arrived while the dose was being escalated, and eased as treatment went on.[3] Wegovy's records that gastrointestinal reactions were most frequently reported during dosage escalation.[1]

The trials say it too. In the 68-week semaglutide trial, nausea and diarrhea were described by the investigators as typically transient, mild to moderate, and subsiding with time.[5] On semaglutide, diarrhea is the one of the three that did not rise when the dose was tripled, as set out in [GLP-1 diarrhea: what has actually been tested](https://glpwatchdog.org/research/glp1-diarrhea-what-helps). In the 72-week tirzepatide obesity trial, which built in a 20-week escalation period, the gastrointestinal events occurred primarily during that period.[6] So a reader at week 30 on an unchanged dose and a reader at week 30 who moved up last Tuesday are asking different questions, even though both would type the same thing into a search box. The practical nausea questions, from what to eat to when vomiting is a red flag, are answered one by one in [our nausea Q&A](https://glpwatchdog.org/research/qna/top-glp1-nausea-management-questions-reddit-answered).

The labels also set the escalation intervals. Treat them as facts about the approved products, not as anything to act on yourself. Zepbound's label sets increases at 2.5 mg a step, with a floor of four weeks on the current dose before the next one.[3] Wegovy's injection label titrates on the same four-week interval, and adds a provision people rarely hear about: where a dose is not tolerated on the way up, a prescriber may consider holding the escalation back by four weeks.[1] That clause describes what the label permits a clinician to do. The way to use it is to raise tolerability at your next appointment.

> **Do not take that as a schedule to run yourself.** It is here because plenty of people assume the ladder is fixed and their only options are to endure or quit, when the label does contain a tolerability provision. What the provision is worth depends on your history, your other medicines and your reason for taking the drug, and none of that is on this page.

Between appointments, many telehealth plans put someone else in the loop. [Medsol RX](https://glpwatchdog.org/reviews/medsol-rx) includes a care coach in every plan, [Livbetr](https://glpwatchdog.org/reviews/livbetr) pairs patients with a one-to-one care coach, and [Lighter You](https://glpwatchdog.org/reviews/lighter-you) adds dietitian visits and care coaching to its membership. [Eloria](https://glpwatchdog.org/reviews/eloria) lists coaching and round-the-clock support, and [eMI Aesthetics](https://glpwatchdog.org/reviews/emi-aesthetics) and [iThriveMD](https://glpwatchdog.org/reviews/ithrivemd) include coaching too. That help can make a rough escalation week easier to eat through, but a coach is not a prescriber; holding a dose back is still the clinician’s decision.

A few programs build in more structured contact. [Marek Health](https://glpwatchdog.org/reviews/marek-health) pairs a health coach with repeat lab panels and provider visits every six months, and [Reset Solutions](https://glpwatchdog.org/reviews/reset-solutions), a physician-led clinic near The Woodlands, Texas, combines coaching with an in-person kickoff and a progress app. [G-Plans](https://glpwatchdog.org/reviews/g-plans) builds its subscription around meal plans matched to your metabolism and includes coaching, which speaks to the food side of a hard week. [Ivim Health](https://glpwatchdog.org/reviews/ivim-health)’s membership, billed as a $75 monthly program fee, includes unlimited provider visits, weekly dose adjustments and functional health coaches.

## How long a single dose is actually in you

This is where the intuition from ordinary medicines misleads people. A weekly GLP-1 injection is not a pill that clears overnight, and both labels put numbers on it.

*Elimination figures as printed in the approved prescribing information for each product.*

|   | Semaglutide | Tirzepatide |
| --- | --- | --- |
| Elimination half-life | About 1 week[1][2] | About 5 days (Mounjaro); 5 to 6 days in overweight or obesity (Zepbound)[3][4] |
| Time to steady state on weekly dosing | Not printed as an interval. Both labels report steady-state concentrations by dose without saying how long they take to reach[1][2] | After 4 weeks of once-weekly administration[3] |
| Still present after the last dose | About 5 weeks (Ozempic); about 5 to 7 weeks at the higher Wegovy doses[1][2] | Not stated as a duration; the overdose section directs observation with the roughly 5-day half-life in mind[3] |
| What the label does with that fact | Wegovy is to be stopped two months ahead of any planned pregnancy, and the label names the long half-life as the reason[1] | Overdose management may require a period of observation given the half-life[3] |

That table has three consequences. A symptom that starts two days after an injection is not necessarily “from that shot” in any clean way, because the previous doses have not left. An effect that troubles you is unlikely to disappear the day after a missed injection. And if a dose has gone wrong, the labels themselves anticipate a period of observation measured in days rather than hours. That is why a bad reaction calls for a clinician who can watch it, not a timer.

It also explains a pattern people report and then doubt: feeling different for weeks after stopping. The Wegovy label's instruction to stop two months ahead of any planned pregnancy is an official acknowledgment that the drug lingers.[1] Stopping, and when, is a conversation with a prescriber; what to expect after the last dose is set out in [stopping Ozempic or Wegovy](https://glpwatchdog.org/research/stopping-semaglutide-weight-regain). If the reason you are considering it is that a program has ended or repriced, we walk through the options in [what to do when a compounded GLP-1 program ends](https://glpwatchdog.org/research/compounded-glp1-going-away-what-to-do), and every seller we track carries a dated figure on the [price tracker](https://glpwatchdog.org/price-tracker).

## What usually settles, and what does not follow that shape

The gastrointestinal cluster is the part that mostly follows a settling pattern. Nausea, vomiting, diarrhea, constipation, reflux, burping and abdominal discomfort dominate both labels' adverse reaction sections.[1][3] The Wegovy label says its stomach reactions were reported most often during the dose increases, and Zepbound's says the same of nausea, vomiting and diarrhea.[1][3] Constipation is the exception that runs longer, as [the constipation guide](https://glpwatchdog.org/research/glp1-constipation-what-works) explains, and nobody has measured how long stomach pain lasts; [the stomach-pain guide](https://glpwatchdog.org/research/glp1-stomach-pain-when-to-worry) covers what the trials do show about it. Some people leave anyway: permanent discontinuation for a gastrointestinal reaction ran 4.3 percent against 0.7 percent on placebo in the Wegovy adult weight trials, and 4.5 percent against 0.8 percent in the semaglutide trial.[1][5] Zepbound's label adds when those exits happened. Most of the people who stopped for an adverse reaction did so in the first few months.[3]

Other effects do not follow that pattern, and the Wegovy label documents one of them in unusual detail. It describes dysesthesia (altered skin sensation, tingling, burning, tenderness), reported by 22 percent of patients at the 7.2 mg dose against 6 percent at 2.4 mg and 0.3 percent on placebo. Among 288 patients who had it at the higher dose, 18 percent had no reported recovery by the end of the trial, and for most of them the dose was never changed. Of the patients who did recover after something was done and were then moved back up to 7.2 mg, 17 of 38 had it again.[1]

Marketing copy does not say this. The label says an effect can persist, that not intervening was associated with not recovering, and that re-escalation brought it back in nearly half of those who tried. The finding is specific to one molecule at one dose and does not support a claim about the whole class. The habit it suggests does carry over: if an effect is not settling, tell someone instead of waiting longer.

A third category is not a duration question at all. Gallbladder disease, pancreatitis and kidney injury from dehydration are events with a labeled warning on both products.[1][3] They do not have a typical timeline, because they are not the sort of thing you wait out.

## The same-day list

These are drawn from the warnings and the patient information in the approved labels. They are not a diagnosis and not an exhaustive list. They are symptoms that should not be watched at home.

- **Abdominal pain that is severe, or that will not go away, and that sometimes reaches through to the back.** Nausea and vomiting may or may not come with it. Both labels use that picture to describe possible acute pancreatitis, and both direct that treatment stop where pancreatitis is suspected. That is a clinician's call, made the same day.[1][3]
- **Vomiting beyond about a day with nothing staying down, or the signs of dehydration.** The labeled route to kidney injury on these drugs runs through volume depletion caused by vomiting or diarrhea, and postmarketing reports include cases needing hemodialysis.[1][3]
- **Pain high in the abdomen, a fever, skin or eyes turning yellow, or stools that have gone clay-colored.** The Zepbound patient information lists exactly these as gallbladder symptoms to report right away.[3]
- **Swelling around the mouth, the tongue or the throat; difficulty breathing or swallowing; a severe rash; fainting.** The label's instruction here is to stop and get medical help right away. Anaphylaxis and angioedema are both on the record as serious hypersensitivity reactions to this drug.[3]
- **Anything that arrived suddenly and is not easing on an unchanged dose.** The pattern in the evidence is escalation-linked and improving. A symptom that does not fit that pattern is worth a call for that reason alone.

> **We are a register, not a clinic.** We can tell you what an approved label says and what a trial counted. We cannot tell you whether your symptom is the ordinary one or the serious one, and neither can any page that has not examined you. That question belongs with a clinician.

## Does it depend which drug you are on?

Less than the marketing implies, at least for the serious end of the gastrointestinal spectrum. A cohort study of routine practice in adults with type 2 diabetes matched new users of dulaglutide, subcutaneous semaglutide and tirzepatide into three pairwise comparisons (65,238, 20,893 and 46,620 matched pairs) and looked at a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation. The hazard ratios were 0.96, 0.96 and 1.07, with confidence intervals crossing 1 in every comparison.[7]

The authors' own conclusion was that the three drugs have similar gastrointestinal safety profiles, and their own stated limitation was possible residual confounding by glycemic control and body mass index.[7] It is a database study rather than a randomized comparison, and it covers severe events rather than everyday nausea. Within those limits, it is the best available answer to “would switching molecules fix this”, and the answer is that it might not.

## If your vial was compounded, one variable is not fixed

Everything above assumes the amount you took is the amount your prescription says. With an approved pen that is a manufacturing guarantee. With a compounded vial the concentration is chosen by the pharmacy, so the volume that delivers a given dose is not standardized between suppliers, and FDA has reported adverse events, some requiring hospitalization, that may relate to patients measuring and self-administering incorrect doses of compounded semaglutide.[8]

That matters here for one specific reason: an unexpectedly large dose and an ordinary dose produce symptoms from the same list, so “how long will this last” cannot be answered without knowing which one happened. Ask the pharmacy for the concentration in milligrams per milliliter and take the number to your prescriber. We take that problem apart in [compounded tirzepatide side effects](https://glpwatchdog.org/research/compounded-tirzepatide-side-effects), the multi-year picture is in [tirzepatide long-term side effects](https://glpwatchdog.org/research/tirzepatide-long-term-side-effects), and which pharmacy is behind a given program is recorded in our [pharmacy register](https://glpwatchdog.org/pharmacies) and on the [compounded tirzepatide board](https://glpwatchdog.org/best/compounded-tirzepatide).

## Frequently asked questions

### How long do semaglutide side effects last?

In the pivotal 68-week trial the investigators described nausea and diarrhea as typically transient, mild to moderate, and subsiding with time, and the Wegovy label records that gastrointestinal reactions were most frequently reported during dosage escalation. So they cluster around dose increases and ease on a steady dose; they do not last a fixed number of weeks. The half-life runs to roughly seven days, and the labels say the drug is still circulating some five weeks after a last dose, or as long as seven at the higher Wegovy doses, so effects do not switch off with a single missed injection. Anything that is not easing belongs with your prescriber.

### How long do tirzepatide side effects last?

The Zepbound label records that most of the nausea, the vomiting and the diarrhea arrived while the dose was going up, and eased afterward, and that most patients who quit over an adverse reaction did so within the first few months. The half-life is around five days, and concentrations settle after four weeks of weekly dosing, so a dose is still working on you well after the day you took it. Those are trial and label patterns across thousands of people, not a forecast for one person.

### Why did the side effects come back when I had been fine for months?

The commonest reason in the evidence is that something changed on the ladder. Both approved labels place the gastrointestinal burden at dose escalation rather than spreading it evenly, so a step up can reset the experience even after a settled stretch. With a compounded vial there is a second possibility, which is that the concentration changed when the supplier did, so the same prescription meant a different amount. Either way the next step is the prescriber, with the concentration figure from the pharmacy in hand.

### How long after stopping does a GLP-1 leave my system?

For semaglutide the labels are explicit. The half-life is roughly seven days, and the Ozempic label puts the drug in the bloodstream for around five weeks after a last dose, with Wegovy stretching that to five or even seven weeks at its own doses. It is for that reason that Wegovy is to be stopped two months ahead of any planned pregnancy. Tirzepatide's half-life is around five days, and its label does not print an equivalent circulation figure, though its overdose section directs a period of observation with that half-life in mind.

### Would switching to a different GLP-1 make this stop?

Possibly, but do not assume it. A large cohort study across three pairwise comparisons in type 2 diabetes found similar rates of severe gastrointestinal events for dulaglutide, semaglutide and tirzepatide, with every hazard ratio close to 1. That study covered serious events rather than everyday nausea, and the authors flagged possible residual confounding. Switching molecules is a clinical decision with its own consequences for coverage and cost, and it is one to make with a prescriber rather than on a forum.

### Should I skip a dose until I feel better?

That is not a decision to take from a website, and we will not give you a rule for it. The labels do anticipate the question: Wegovy's says a prescriber may consider delaying an escalation by four weeks if a patient does not tolerate a dose. That provision exists for a clinician to use, and the way to reach it is to describe what you are experiencing to the person who wrote your prescription.

## References

1. Novo Nordisk WEGOVY (semaglutide) injection and tablets — prescribing information (sections 2.2, 5, 6.1, 8.3, 10, 12.3). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Novo Nordisk OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information (sections 10, 12.3). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
3. Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information (sections 2.1, 5, 6.1, 10, 12.3, patient information). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
4. Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information (section 12.3). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. 2021. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387(3):205-216. 2022. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
7. Crisafulli S, Alkabbani W, Paik JM, et al. Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. Ann Intern Med 2026;179(1):1-11. 2026. PMID: 41183330. https://pubmed.ncbi.nlm.nih.gov/41183330/
8. U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA Drug Safety and Availability. 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

---

Cite as: GLP Watchdog, Ruth Calder, "How Long Do Semaglutide and Tirzepatide Side Effects Last?", published 2026-08-14, updated 2026-11-02. https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last

Canonical HTML page: https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
